GlassScriptPhysician profile
Ashish B Parikh
NPI 1649247487
$26,365.51
in general payments reported to CMS, 2019-2025
29 companies · $745 in 2025
The $745 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $35.85 · 2021: $271 · 2022: $197 · 2023: $13K · 2024: $809 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $13K · Food and Beverage: $2,128 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $12,666.67 |
| Food and Beverage | $2,127.96 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $12,688.10 | 2022-2023 | Auryon Laser System 100-120 Vac |
| Janssen Pharmaceuticals, INC | $10,741.20 | 2019-2024 | Xarelto |
| Abbott Laboratories | $629.97 | 2019-2025 | Ensite, Cardiomems, Merlin@Home |
| Pfizer INC. | $380.47 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $302.03 | 2022-2025 | Verquvo, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.43 | 2023-2024 | Jardiance |
| Novo Nordisk INC | $208.28 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $153.77 | 2021-2024 | Brilinta |
| Boston Scientific Corporation | $129.73 | 2019-2025 | Latitude Communicator Power Supply, Bodyguardian |
| Lemaitre Vascular, INC. | $94.19 | 2025 | Trivex System |
| Lexicon Pharmaceuticals, INC. | $80.65 | 2023 | Inpefa |
| Cardiovascular Systems INC. | $80.62 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $79.45 | 2019-2023 | Lifevest |
| Novartis Pharmaceuticals Corporation | $76.62 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $67.48 | 2023-2024 | Eliquis, Camzyos |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $62.60 | 2024 | |
| Esperion Therapeutics, INC. | $57.65 | 2023-2025 | Nexletol |
| Digirad Health, INC | $54.33 | 2019 | |
| Janssen Scientific Affairs, LLC | $53.40 | 2019 | |
| Philips North America LLC | $46.10 | 2024-2025 | Ambulatory Monitoring & Diagnostics Undivided, (6554) Peripheral Vascular Undivided |
| Terumo Medical Corporation | $42.00 | 2023 | Angio-Seal, Glidewire, Glidesheath Slender |
| Heartflow, INC. | $25.76 | 2024 | |
| Alnylam Pharmaceuticals INC. | $22.61 | 2025 | |
| Scpharmaceuticals INC. | $19.74 | 2025 | |
| Tactile Systems Technology INC | $16.32 | 2025 | Nimbl, Flexitouch Plus |
| Medtronic, INC. | $13.16 | 2021 | |
| Medtronic Vascular, INC. | $11.23 | 2019 | |
| Acarix USA INC. | $8.62 | 2023 | Cadscor System |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.